The Application of High-Throughput RNAi in Pancreatic Cancer Target Discovery and Drug Development

  • Hongwei Yin
  • Jeff Kiefer
  • Michelle Kassner
  • Nanyun Tang
  • Spyro Mousses


Pancreatic cancer is a particularly lethal malignancy and is highly chemoresistant. There is an urgent need for the identification of new therapeutic targets and more effective treatment options. New approaches, such as high-throughput RNAi, enable the functional evaluation of the casual role of numerous genes in regulating cellular processes, such as cell survival and drug response. In the following chapter, we review RNA interference and its application in high-throughput biology. Specifically, an overview is provided highlighting important experimental aspects in transitioning RNAi to a high-throughput platform. In addition, there is a brief review of current applications of high-throughput RNAi for cancer target identification and drug discovery. Lastly, particular applications of genome-scale RNAi to pancreatic cancer target and treatment identification are discussed. In summary, genome-scale RNAi is proving to be a powerful cellular genomics technology that holds great promise for advancing pharmacologically relevant targets and agents in pancreatic cancer research.


Pancreatic Cancer Pancreatic Cancer Cell Line RNAi Screen siRNA Screen siRNA Library 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bagga S, Bracht J, Hunter S et al (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122:553–563CrossRefPubMedGoogle Scholar
  2. Bartz SR, Zhang Z, Burchard J et al (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26:9377–9386CrossRefPubMedGoogle Scholar
  3. Berns K, Hijmans EM, Mullenders J et al (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428:431–437CrossRefPubMedGoogle Scholar
  4. Bohnsack MT, Czaplinski K, Gorlich D (2004) Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10:185–191CrossRefPubMedGoogle Scholar
  5. Boutros M, Ahringer J (2008) The art and design of genetic screens: RNA interference. Nat Rev Genet 9:554–566CrossRefPubMedGoogle Scholar
  6. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247CrossRefPubMedGoogle Scholar
  7. Brummelkamp TR, Fabius AW, Mullenders J et al (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2:202–206CrossRefPubMedGoogle Scholar
  8. Caldwell JS (2007) Cancer cell-based genomic and small molecule screens. Adv Cancer Res 96:145–173CrossRefPubMedGoogle Scholar
  9. Ceyhan GO, Bergmann F, Kadihasanoglu M et al (2007) The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis. Gut 56:534–544CrossRefPubMedGoogle Scholar
  10. Dai H, Li R, Wheeler T et al (2007) Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol 38:299–307CrossRefPubMedGoogle Scholar
  11. Davis RE, Brown KD, Siebenlist U et al (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861–1874CrossRefPubMedGoogle Scholar
  12. Duxbury MS, Ito H, Benoit E et al (2005) RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 11:3433–3438CrossRefPubMedGoogle Scholar
  13. Echeverri CJ, Beachy PA, Baum B et al (2006) Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3:777–779CrossRefPubMedGoogle Scholar
  14. Echeverri CJ, Perrimon N (2006) High-throughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 7:373–384CrossRefPubMedGoogle Scholar
  15. Elbashir SM, Harborth J, Lendeckel W et al (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498CrossRefGoogle Scholar
  16. Elbashir SM, Lendeckel W, Tuschl T (2001b) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200CrossRefGoogle Scholar
  17. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811CrossRefPubMedGoogle Scholar
  18. Giroux V, Iovanna J, Dagorn JC (2006) Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20:1982–1991CrossRefPubMedGoogle Scholar
  19. Hammond SM, Boettcher S, Caudy AA et al (2001) Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293:1146–1150CrossRefPubMedGoogle Scholar
  20. Iorns E, Lord CJ, Ashworth A (2009) Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 417:361–370CrossRefPubMedGoogle Scholar
  21. Iorns E, Lord CJ, Turner N et al (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6:556–568CrossRefPubMedGoogle Scholar
  22. Iorns E, Turner NC, Elliott R et al (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91–104CrossRefPubMedGoogle Scholar
  23. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMedGoogle Scholar
  24. Kennerdell JR, Carthew RW (1998) Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 95:1017–1026CrossRefPubMedGoogle Scholar
  25. Kimmelman AC, Hezel AF, Aguirre AJ et al (2008) Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA 105:19372–19377CrossRefPubMedGoogle Scholar
  26. Konig R, Chiang CY, Tu BP et al (2007) A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 4:847–849CrossRefPubMedGoogle Scholar
  27. Kuuselo R, Savinainen K, Azorsa DO et al (2007) Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 67:1943–1949CrossRefPubMedGoogle Scholar
  28. Lord CJ, McDonald S, Swift S et al (2008) A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7:2010–2019CrossRefGoogle Scholar
  29. Lund E, Guttinger S, Calado A et al (2004) Nuclear export of microRNA precursors. Science 303:95–98CrossRefPubMedGoogle Scholar
  30. MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7:591–600CrossRefPubMedGoogle Scholar
  31. Misquitta L, Paterson BM (1999) Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): a role for nautilus in embryonic somatic muscle formation. Proc Natl Acad Sci USA 96:1451–1456CrossRefPubMedGoogle Scholar
  32. Morgan-Lappe S, Woods KW, Li Q et al (2006) RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25:1340–1348CrossRefPubMedGoogle Scholar
  33. Morgan MA, Parsels LA, Parsels JD et al (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:6835–6842CrossRefPubMedGoogle Scholar
  34. Ngo VN, Davis RE, Lamy L et al (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106–110CrossRefPubMedGoogle Scholar
  35. Paddison PJ, Caudy AA, Sachidanandam R et al (2004a) Short hairpin activated gene silencing in mammalian cells. Methods Mol Biol 265:85–100Google Scholar
  36. Paddison PJ, Silva JM, Conklin DS et al (2004b) A resource for large-scale RNA-interference-based screens in mammals. Nature 428:427–431CrossRefGoogle Scholar
  37. Perrimon N, Friedman A, Mathey-Prevot B et al (2007) Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens. Drug Discov Today 12:28–33CrossRefPubMedGoogle Scholar
  38. Pillai RS, Bhattacharyya SN, Artus CG et al (2005) Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309:1573–1576CrossRefPubMedGoogle Scholar
  39. Schlabach MR, Luo J, Solimini NL et al (2008) Cancer proliferation gene discovery through functional genomics. Science 319:620–624CrossRefPubMedGoogle Scholar
  40. Turner NC, Lord CJ, Iorns E et al (2008) A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27:1368–1377CrossRefPubMedGoogle Scholar
  41. Wang H, Han H, Von Hoff DD (2006) Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 66:9722–9730CrossRefPubMedGoogle Scholar
  42. Whitehurst AW, Bodemann BO, Cardenas J et al (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815–819CrossRefPubMedGoogle Scholar
  43. Yu JY, DeRuiter SL, Turner DL (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99:6047–6052CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Hongwei Yin
    • 1
  • Jeff Kiefer
  • Michelle Kassner
  • Nanyun Tang
  • Spyro Mousses
  1. 1.Clinical Translational Research DivisionTranslational Genomics Research InstituteScottsdaleUSA

Personalised recommendations